Page 4 - Andreas Muehler News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Phase 2 trial of vidofludimus calcium in progressive MS fully enrolled | Study to show if potential seen with RRMS extends to PPMS, SPMS

Phase 2 trial of vidofludimus calcium in progressive MS fully enrolled | Study to show if potential seen with RRMS extends to PPMS, SPMS
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

United statesDaniel vittAndreas muehlerImmunic therapeuticsNorth america

EQS-News: Immunic, Inc : Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

EQS-News: Immunic, Inc : Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesEdna kaplanPaula schwartzDaniel vittAndreas muehlerJessica breuImmunic incExchange commissionRx communications groupDistribution servicesCompletes enrollmentIts phaseVidofludimus calciumProgressive multiple sclerosisProgressive multipleInterim biomarker analysis expected

Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

/PRNewswire/ Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for.

United statesPaula schwartzAndreas muehlerJessica breuDaniel vittEdna kaplanExchange commissionRx communications groupImmunic inc nasdaqImmunic incUnblinded interim biomarker analysis expectedFull data readout expectedChief executive officerChief medical officerNorth americaEastern europe

EQS-News: Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

Issuer: Immunic, Inc. / Key word(s): Study Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis 17.08.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic Completes Enrollment of Its P.

United statesJessica breuDaniel vittEdna kaplanPaula schwartzAndreas muehlerExchange commissionImmunic incDistribution servicesRx communications groupCompletes enrollmentIts phaseVidofludimus calciumProgressive multiple sclerosisProgressive multipleUnblinded interim biomarker analysis expected

Vidofludimus calcium tolerated well nearly 4 years in RRMS trial | Multiple Sclerosis News Today

Vidofludimus calcium tolerated well nearly 4 years in RRMS trial | Multiple Sclerosis News Today
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

Andreas muehlerConsortium of multiple sclerosis centersMultiple sclerosis centersAnnual meetingLong term safetyVidofludimus calciumRelapsing remitting multiple sclerosisOpen label extension periodImmunic therapeuticsMultiple sclerosis news